Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer : vimarsana.com

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Alexandra Santos , Akoya Biosciences , Peter Blume Jensen , Breakthrough Devices Program , Acrivon Therapeutics Inc , Exchange Commission , Drug Administration , Acrivon Predictive Precision Proteomics , Breakthrough Device , Fast Track , Private Securities Litigation Reform Act , Media Contacts ,